ABOUT LIRAGLUTIDE INJECTION

What is liraglutide injection?

Liraglutide injection is an injectable prescription medicine used along with diet and exercise to improve blood sugar (glucose) in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular events, such as heart attack, stroke, or death, in adults with type 2 diabetes mellitus and established cardiovascular disease.
Liraglutide injection should be used as prescribed by a healthcare provider.

Do not use liraglutide injection if you or any of your family members have ever had medullary thyroid carcinoma (MTC) or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Do not use liraglutide injection if you have had a serious allergic reaction to liraglutide or any of its ingredients.

Serious side effects, including the potential development of thyroid tumors or cancer, may occur.
Tell your healthcare provider right away if you experience a lump or swelling in your neck, hoarseness, difficulty swallowing, or shortness of breath, as these may be symptoms of thyroid cancer.
Liraglutide injection is contraindicated for individuals with a personal or family history of MTC or MEN 2.

USING THE PEN

Never share your liraglutide injection pen with anyone else, even if you use a new needle. Sharing can spread serious infections between you and others.

Read the Instructions for Use that come with liraglutide injection.
Always use liraglutide injection exactly as your healthcare provider tells you to.
Your healthcare provider should show you how to use liraglutide injection before you use it for the first time.

Liraglutide injection is injected under the skin (subcutaneously) in your stomach area (abdomen), upper leg (thigh), or upper arm. Do not inject into a muscle or vein.
Rotate your injection site with each injection and do not use the same site for each injection.

Liraglutide injection is injected once daily, at any time during the day. It may be taken with or without food.

Yes. Before your first injection with each new pen, check the liraglutide injection flow as described in the Instructions for Use. If no drop appears after repeating the flow‑check steps, change the needle and repeat the procedure. If a drop still does not appear, do not use the pen and contact Biocon Pharma Inc.

After your injection, carefully remove the needle and place it in a sharps container right away to reduce the risk of needle sticks.
Do not throw used needles in household trash. Follow the Instructions for Use and local disposal guidelines.

DOSING & MISSED DOSES

Start liraglutide injection with 0.6 mg once daily for one week. After one week, increase to 1.2 mg once daily.
If additional glycemic control is required, increase to a maximum dose of 1.8 mg once daily after at least one week on the 1.2 mg dose.

If you miss a dose of liraglutide injection, take the missed dose at the next scheduled dose. Do not take 2 doses of liraglutide injection at the same time

STORAGE

Store new, unused pens in a refrigerator at 36°F to 46°F (2°C to 8°C).
A pen in use may be stored at room temperature (59°F to 86°F / 15°C to 30°C) or in the refrigerator.
Do not freeze liraglutide injection. Throw away the pen 30 days after first use, even if medicine remains.

SIDE EFFECTS

Liraglutide injection may cause serious side effects, including pancreatitis, low blood sugar (especially when used with insulin or sulfonylureas), increased heart rate, kidney problems from dehydration, severe stomach problems, serious allergic reactions, gallbladder problems, depression or thoughts of suicide, and food or liquid entering the lungs during anesthesia or deep sedation.
The most common side effects include nausea, diarrhea, vomiting, constipation, injection‑site reactions, headache, dizziness, fatigue, upset stomach, stomach pain, and changes in digestive enzymes.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1‑800‑FDA‑1088.

Scroll to Top

You are now departing from the Liraglutide Type 2 Diabetes patient website and redirected to the Biocon Biologics corporate website. Please be aware that the Biocon Biologics corporate website may contain information that varies from the content on the Liraglutide Type 2 Diabetes patient website. The website you are about to access is the corporate website located outside of the U.S.
U.S. regulations may not be applicable to the content on this corporate website.

INDICATIONS

You are now leaving the liraglutide type 2 diabetes patient website. Liraglutide injection is a prescription medicine indicated as an adjunct to diet and exercise to improve blood sugar (glucose) in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease.

Biocon Limited Inc. assumes no responsibility for and makes no warranties or representation of any kind as to the accuracy, currency, or completeness of any information contained in such third-party website, including any third-party social media or mobile application platform. Inclusion of any third-party link on this website does not imply an endorsement or recommendation by Biocon Limited, and a link to this website from another website does not imply a relationship between Biocon Limited and any third party. Your use of any such third-party site or platform is at your own risk and will be governed by such third party’s terms and policies (including its privacy policy). Biocon Limited shall not be liable for any direct, indirect, consequential, incidental or punitive damages arising out of access to, use of, or inability to use such third-party website, or any errors or omissions in the content thereof.